$11.9M
+$11.9M this year1 filing since 2026 · latest SAFE filed
Kayak Therapeutics is a privately held oncology biotechnology company developing small-molecule cancer therapies against validated clinical pathways. Its lead effort targets TRIM7, an E3 ligase implicated in RTK/RAS pathway-driven tumor proliferation, with preclinical data describing activity independent of mutation status and in the setting of KRAS-inhibitor resistance. The company was founded in 2025 by Josiah Hornblower, a co-founder and former CEO of Shattuck Labs (Nasdaq: STTK), with George Fromm, PhD as scientific founder and Chief Scientific Officer. It operates out of Austin and Houston, Texas and Durham, North Carolina.
What sets it apart
A first-in-class covalent TRIM7 inhibitor aimed at RTK/RAS-driven tumors regardless of mutation status, including tumors that have become resistant to KRAS inhibitors, and at restoring tumor-intrinsic interferon responsiveness.
A first-in-class covalent small-molecule inhibitor of TRIM7 in preclinical development for solid tumors driven by the RTK/RAS pathway.
